Navigation Links
PTC Therapeutics Closes $30 Million Financing
Date:7/23/2012

SOUTH PLAINFIELD, N.J., July 23, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing investors. 

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

"This funding will support our continued late-stage clinical development of ataluren in nonsense mutation Duchenne and Becker muscular dystrophy and nonsense mutation cystic fibrosis," stated Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "This is our first equity financing round in over two years, and serves as an important validation of the ataluren program and our commitment for its further development." 

PTC recently announced results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis. An extension study for patients previously enrolled in the trial is ongoing. An open-label trial for Duchenne and Becker muscular dystrophy patients who received ataluren in a prior, PTC-sponsored clinical study is also ongoing while PTC continues the dialogue with regulatory authorities regarding next steps in ataluren's development. In both Duchenne and Becker muscular dystrophy and cystic fibrosis, ataluren has demonstrated clinically meaningful trends in the primary endpoints and in supporting secondary endpoints. It was generally well tolerated; serious adverse events were infrequent and not considered to be related to the drug. PTC owns the worldwide rights for ataluren across all indications.

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
2. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
3. Echo Therapeutics Expands License Agreement with Ferndale Pharma
4. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
5. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
6. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
7. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
8. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
9. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
10. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
11. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ATLANTA , June 30, 2015 Legal-Bay ... the first bellwether trial in the multidistrict litigation (MDL) ... scheduled to begin October 13 th , 2015. There ... Inc. which have been consolidated before a federal judge ... that the first bellwether trial will begin in October ...
(Date:6/29/2015)... June 29, 2015  New guidelines released today ... Association give hope for better outcomes to the ... acute ischemic stroke each year. Stryker,s Trevo ® ... used in the clinical trials that provided data ... guidelines strongly recommend endovascular therapy with stent retrievers ...
(Date:6/29/2015)... -- Allergan plc (NYSE: AGN ) today announced ... financial results on Thursday, August 6, 2015, prior ... Company will host a conference call and webcast ... August 6, 2015 to discuss its financial results. The ... Canada (877) 251-7980, International (706) ...
Breaking Medicine Technology:Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast 2Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast 3
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), ... development, manufacture and sale of enzyme and protein ... industries, today announced financial results for the quarter ... in this press release should be read in ...
... Southern Home Medical Equipment, Inc. (PINKSHEETS: SHOM), a ... equipment to medical institutions, announced today that Encore ... significant growth from Encore Medical Staffing operations in ... started this franchise in December, 2010," says Dr. ...
Cached Medicine Technology:Dyadic International Reports 2011 First Quarter Financial Results 2Dyadic International Reports 2011 First Quarter Financial Results 3Dyadic International Reports 2011 First Quarter Financial Results 4Dyadic International Reports 2011 First Quarter Financial Results 5Southern Home Medical Equipment Reports Significant Growth from Encore Franchisees 2
(Date:6/30/2015)... St. Louis, MO (PRWEB) , ... June 30, ... ... , attorneys handling national testosterone claims alleging heart attack and stroke incidents are ... place after Independence Day. The Case Management Conference is scheduled for July 9, ...
(Date:6/30/2015)... Diego, CA (PRWEB) , ... June 30, 2015 ... ... brand, Liporidex, announced today a partnership with Knockout Zone Miami (KO ... Taekwondo, strength and conditioning specialist and CrossFit Coach, Diego de Vera. The partnership ...
(Date:6/30/2015)... ... June 30, 2015 , ... Amerec, a division of TyloHelo Inc, is ... AEC Daily is now approved by the Interior Design Continuing Education Council for 1 ... an overview and explanation of what sauna, steam, and far-infrared saunas are, where they ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... be expedited through the use of new forms, according to attorneys handling ... Complaint and the Short Form Complaint, “provide guidance” for plaintiffs’ attorneys in filing ...
(Date:6/30/2015)... Jersey City, NJ (PRWEB) , ... June 30, 2015 , ... ... devices, today announced the general availability of three new apps – AvePoint Watermark, ... and SharePoint Online. With the addition of these apps, workers can better streamline everyday ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 2Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 3Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 4Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 2Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 3Health News:Amerec’s Steam and Sauna Continuing Education Course Now Approved for Interior Design Credit 2Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 2Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 2Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 4
... White,s Cancer Research Institute (CRI) is conducting a clinical trial ... Lymphoma, which affects the white blood ... B-cell or T-cell. About 85% of lymphomas are of B-cell ... primarily chronic, but they do not respond well to chemotherapy. ...
... (GSA) the nation,s largest interdisciplinary organization devoted to ... PhD, of Cornell University as the 2010 recipient of ... honor recognizes a significant contribution in gerontology that has ... service, prevention, amelioration of symptoms or barriers, or a ...
... Reporter , WEDNESDAY, July 14 (HealthDay News) -- The controversial ... more than other medications of its kind but should stay ... panel recommended late Wednesday. By a complex series of ... the U.S. Food and Drug Administration remove Avandia from the ...
... by our work is its relevance to population and ... survival related to cancer in a more precise way", ... researcher in the Epidemiology Service of the Department of ... The investigation, which has been published in the journal ...
... by cancer cells allows for a better understanding of ... personalized approach to treatment. But obtaining the RNA from ... the genetic analysis is a challenging prospect. Currently, lung ... early-stage tumors removed during surgery. The small quantities of ...
... N.C. -- A team of Duke University researchers and ... spread of malaria while protecting human and environmental health. ... disease occurs will be supported by a $2.2 million, ... "We,ll be performing experiments in 24 villages in ...
Cached Medicine News:Health News:Pillemer wins GSA's 2010 M. Powell Lawton Award 2Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 2Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 3Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 4Health News:The probability of surviving nine types of cancer is analyzed 2Health News:New method of tissue banking makes gene analysis more practical for lung cancer 2Health News:Duke and African partners to study sustainable malaria control 2
... factor I (IGF-I or somatomedin C) is a ... It acts as a potent mitogen of cellular ... cell-surface receptors. In the circulation, IGF-I is bound ... the actions of IGF-I by modulating the interaction ...
... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
Medicine Products: